Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 447 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: IV Fluids Clear all
Completed Phase 2 Interventional Results available

A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody

NCT03525678
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Belantamab mafodotin frozen liquid, Belantamab mafodotin lyophilized powder
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
21
States / cities
New Haven, Connecticut • Atlanta, Georgia • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 21, 2026, 6:50 AM EDT
Terminated Phase 1Phase 2 Interventional

A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia

NCT04899310
View directory record Official record
Conditions
Methylmalonic Acidemia
Interventions
mRNA-3705, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
1 Year and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Los Angeles, California • Palo Alto, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Medical and Surgical Treatment of Uncomplicated Acute Appendicitis in Children

NCT02991937
View directory record Official record
Conditions
Appendicitis
Interventions
Piperacillin/Tazobactam, Surgical Treatment
Drug · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
6 Years to 17 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 21, 2026, 6:50 AM EDT
Terminated Not applicable Interventional

Early Administration of Long-acting Insulin Treatment of Diabetic Ketoacidosis in Pediatric Type 1 Diabetes

NCT02548494
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetic Ketoacidosis
Interventions
Glargine, IV insulin, Electrolyte Correction, Correction of Fluid Loss
Drug · Other
Lead sponsor
Chattanooga-Hamilton County Hospital Authority
Other
Eligibility
1 Year to 21 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Early Phase 1 Interventional Results available

Effects of Flavors on Nicotine Reinforcement in Smokers

NCT03243630
View directory record Official record
Conditions
Nicotine Dependence
Interventions
IV nicotine, Menthol flavor, green apple, green apple and menthol
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 30 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Phase 1 Interventional

Galantamine Effects on Nicotine Responses in Smokers

NCT01417429
View directory record Official record
Conditions
Smoking, Tobacco Withdrawal
Interventions
Galantamine, IV Nicotine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Oct 21, 2026, 6:50 AM EDT
Recruiting Phase 1 Interventional

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

NCT04929223
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Inavolisib, Bevacizumab, Cetuximab, Atezolizumab, Tiragolumab, SY-5609, Divarasib, FOLFOX, FOLFIRI, FoundationOne®Liquid CDx
Drug · Diagnostic Test
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine and Compare Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam in Healthy Subjects

NCT03303924
View directory record Official record
Conditions
Healthy
Interventions
ETX2514 and sulbactam
Drug
Lead sponsor
Entasis Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Not applicable Interventional

Acupuncture for Pain in Sickle Cell Disease

NCT04122378
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
acupuncture
Other
Lead sponsor
Deepika Darbari
Other
Eligibility
8 Years to 22 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 21, 2026, 6:50 AM EDT
Recruiting Not applicable Interventional

Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas

NCT05676450
View directory record Official record
Conditions
Lymphoma
Interventions
cell-free DNA
Diagnostic Test
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 21, 2026, 6:50 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus

NCT00381810
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Rituximab, Methylprednisolone, Acetaminophen, Diphenhydramine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
16 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
11
States / cities
Paradise Valley, Arizona • San Leandro, California • Boise, Idaho + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Not applicable Interventional

ED Tracking Sheet Implementation

NCT05213923
View directory record Official record
Conditions
Sepsis, Severe Sepsis, Systemic Inflammatory Response Syndrome
Interventions
ED Sepsis Tracking Sheet
Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Phase 1 Interventional

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Stage I-IIIB Non-Small Cell Lung Cancer After Completion of Radiation Therapy Alone or Combined Radiation Therapy and Chemotherapy

NCT00738452
View directory record Official record
Conditions
Lung Cancer
Interventions
high performance liquid chromatography, pharmacological study, radionuclide imaging, single photon emission computed tomography, radiation therapy, yttrium Y 90 anti-CEA monoclonal antibody cT84.66
Other · Procedure · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Two Novel Hydration Beverage Formulas on Rehydration in Adults

NCT06063655
View directory record Official record
Conditions
Dehydration
Interventions
Control: Water, Liquid IV hydration multiplier, Liquid IV sugar-free hydration multiplier
Dietary Supplement
Lead sponsor
University of Memphis
Other
Eligibility
18 Years to 49 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Phase 1 Interventional

Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome

NCT02212561
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS), Mixed Phenotype Acute Leukemia (MPAL)
Interventions
Selinexor, Fludarabine, Cytarabine, methotrexate/hydrocortisone/cytarabine
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 24 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
6
States / cities
Phoenix, Arizona • Palo Alto, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Oct 21, 2026, 6:50 AM EDT
Withdrawn Not applicable Interventional

Early Goal Directed Therapy in Sepsis by Emergency Medical Services

NCT02266654
View directory record Official record
Conditions
Sepsis
Interventions
IV fluids, Hospital Notification
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
17 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Phase 4 Interventional Results available

Evaluating The Safety And Clinical Efficacy Of Elderberry Extract In Patients With Influenza

NCT03410862
View directory record Official record
Conditions
Influenza, Human
Interventions
Elderberry Extract, Placebos
Drug
Lead sponsor
michael macknin
Other
Eligibility
5 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Early Phase 1 Interventional

Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies

NCT01760226
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma, Post Transplant Lymphoproliferative Disorder, Primary Mediastinal (Thymic) Large B-cell Lymphoma
Interventions
DA-EPOCH-R for DLBCL, PTLD, AND PMBCL, Methotrexate, Etoposide, Doxorubicin, Vincristine, Rituximab, Cyclophosphamide, Prednisone, G-CSF
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 30 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase

NCT00807885
View directory record Official record
Conditions
Dehydration
Interventions
hylenex-facilitated subcutaneous Lactated Ringer's infusion
Drug
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Lincoln, Nebraska • Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 26, 2011 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Phase 4 Interventional

Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults

NCT04219540
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
XR-B (SUBLOCADETM), XR-NTX
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
New Haven, Connecticut • Baltimore, Maryland • Hanover, New Hampshire + 3 more
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 21, 2026, 6:50 AM EDT
Recruiting Not applicable Interventional

Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection

NCT05219110
View directory record Official record
Conditions
Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome
Interventions
Infusion of 200% maintenance fluids as balanced crystalloid IV solution, Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution
Other
Lead sponsor
University of Calgary
Other
Eligibility
9 Months to 21 Years
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
22
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 21, 2026, 6:50 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

NCT04512235
View directory record Official record
Conditions
AL Amyloidosis
Interventions
CAEL-101, Placebo, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen
Drug · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
32
States / cities
Scottsdale, Arizona • Duarte, California • Palo Alto, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Phase 2Phase 3 Interventional Results available

TBI Dose De-escalation for Fanconi Anemia

NCT00352976
View directory record Official record
Conditions
Fanconi Anemia
Interventions
Cyclophosphamide, Fludarabine, Total Body Irradiation, Bone Marrow Transplantation, Mycophenolate Mofetil, Sirolimus
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Not listed
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 21, 2026, 6:50 AM EDT
Recruiting Phase 2 Interventional

Belimumab With Rituximab for Primary Membranous Nephropathy

NCT03949855
View directory record Official record
Conditions
Membranous Nephropathy, Nephrotic Syndrome
Interventions
Belimumab, Placebo for Belimumab, Rituximab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 21, 2026, 6:50 AM EDT